Microsoft is making big claims about its AI. Mustafa Suleyman, head of Microsoft AI, says their new diagnostic system beat generalist doctors on hard medical cases. A study in Science supports this. This is not just a lab curiosity. It challenges how medical diagnostics work, potentially saving costs and improving outcomes. But the headline hides a crucial detail: most of the improvement comes from the underlying AI models, not from Microsoft’s specific system.
The core of this story is about who owns the intelligence. Microsoft's system, while impressive, acts more as an orchestrator. It uses powerful large language models (LLMs, the tech behind ChatGPT) to crunch medical data. This means the heavy lifting, the actual 'thinking' that leads to better diagnoses, is done by the foundational AI. It's like a master chef getting credit for a dish, but the real magic is in the ingredients provided by someone else.
This distinction matters for the money. If the performance gains are primarily due to advancements in generic LLMs, then the companies developing those foundational models are the true beneficiaries. These include Google's DeepMind or OpenAI (in which Microsoft has a massive investment). They build the core technology that others then license or integrate. Microsoft's value proposition here is in applying and refining that tech for specific, high-value use cases like medicine.
The implications for healthcare are significant. AI could reliably assist in diagnosing rare diseases or complex conditions. This could reduce misdiagnosis rates and speed up treatment. This could lead to massive cost savings for hospitals and insurance companies, and better health for patients. The revenue potential for AI diagnostic tools is enormous. Projections value the global AI in healthcare market in the tens of billions of dollars annually within the next few years.
However, this also brings up the question of responsibility and regulation. If an AI makes a diagnostic error, who is accountable? The developer of the foundational model? The company that integrated it? The doctor who relied on it? Regulators are still trying to catch up with the speed of AI development. Medical AI, with its direct impact on human lives, will face intense scrutiny. The price of getting this wrong is not just financial, it's human.
On one side, you have the AI innovators pushing the boundaries of what's possible, promising a future of 'medical superintelligence'. On the other, you have the traditional medical establishment, slow to adopt new technologies and rightly concerned about patient safety. The friction between these forces will shape how quickly and broadly these systems are deployed. It's a classic battle between disruption and established practice.
The real winners here are likely the foundational AI model developers, not just Microsoft itself. They build the picks and shovels for the AI gold rush. Microsoft, as a major investor in some of these foundational technologies, benefits indirectly. Its specific diagnostic system might be more of a showcase for what's possible rather than a standalone cash cow. The value is in the underlying intellectual property. For investors, the smart money is on the companies creating the core AI, not just those applying it. As we say in Brazil, 'o que os olhos não veem, o coração não sente' (what the eyes don't see, the heart doesn't feel), and many won't see the foundational tech behind the Microsoft branding.
What to watch next: Keep an eye on the regulatory bodies, particularly in the US and Europe. Watch how they approach AI in high-stakes fields like medicine. Their decisions will dictate the speed of adoption and the liabilities involved. Also, track the specific revenue streams from these AI applications. Is it a licensing model for the underlying LLMs, or is it a subscription for the integrated diagnostic system? That will tell us who is truly monetizing the 'intelligence'.
